[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"disease-free-survival\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:disease-free-survival":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,73,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100472797","phase-2-reduced-mbf-regimen-for-patients-55-years-with-myeloid-malignancies-100472797",false,"NCT05436561","Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies","A Multiple-center Phase II Study to Evaluate the Clinical Outcome of Reduced Conditioning Regimen With Melphalan, Busulfan and Fludarabine for Patients >=55 Years With Myeloid Malignancies.","Inclusion Criteria:\n\n* Age 55-65\n* patients with HLA-matched sibling donors, 9-10\u002F10 matched unrelated donors or haplo-identical donors.\n* patients with AML in remission, or MDS in any stage, or CMML in any stage\n* inform consent provided\n\nExclusion Criteria:\n\n* patients with abnormal liver (\\>3N), renal (1.5N) or cardiac function\n* patients with active infection","ALL","55 Years","65 Years",{"count":20,"type":21},61,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg\u002Fm2), busulfan (6.4mg\u002Fkg) and melphalan (100mg\u002Fm2) in patients with myeloid malignancies including AML, MDS and CMML \\>=55 years.",[27],"Disease-free Survival","RECRUITING","2026-03-15",{"date":31,"type":32},"2026-03-17","ACTUAL",{"date":34,"type":32},"2022-06-01",{"date":36,"type":21},"2027-06-30",{"name":38,"class":39},"Shanghai Jiao Tong University School of Medicine","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":60,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100441118","long-term-follow-up-of-subjects-treated-with-car-t-cells-100441118","NCT05024175","Long-term Follow-up of Subjects Treated With CAR T Cells","Inclusion Criteria:\n\nSubjects will be asked to participate leading up to the last DF\u002FHCC corresponding main study visit.\n\nSubjects meeting the following criteria are eligible for study participation:\n\n* Provision of voluntary written informed consent by subject\n* CAR T cells were administered in DF\u002FHCC IRB corresponding main study\n\nExclusion Criteria:\n\nSubjects meeting the following criterion are to be excluded from study participation:\n\n\\- Subject unable to comply with study requirements","18 Years",{"count":49,"type":21},45,"OBSERVATIONAL","This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF\u002FHCC# 22-175) and NCT06026319 (DF\u002FHCC# 23-474).",[53,54,55,56,57,58,59],"Long Term Adverse Effects","CAR-T","Duty to Follow Up","Adult","Progression-Free Survival","Disease-Free Survival","Overall Survival",[61,62],"Long-Term Follow-up to CAR-T Cells","Follow-up Studies","2026-03-13",{"date":65,"type":32},"2026-03-16",{"date":67,"type":32},"2023-08-07",{"date":69,"type":21},"2039-08-01",{"name":71,"class":39},"Marcela V. Maus, M.D.,Ph.D.",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":72},"100551642","microwave-ablation-versus-liver-resection-for-intrahepatic-cholangiocarcinoma-100551642","NCT06462742","Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma","Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma Within Milan Criteria","MALRIC","Inclusion Criteria:\n\n1. pathologically diagnosed iCCA based on the WHO classifications;\n2. curative-intent liver resection or microwave ablation;\n3. tumor within Milan criteria, namely single tumor ≤5cm in maximum diameter; multiple tumors ≤3 in number and each ≤3cm; no evidence of major vascular\u002Fhilar invasion, extrahepatic\u002Flymphatic metastasis or other malignancies;\n4. age ≥18 years.\n\nExclusion Criteria:\n\nPatients not meeting any one of the inclusion criteria were excluded.",{"count":82,"type":21},1000,"Thermal ablation has been recommended by worldwide guidelines as first-line treatment for hepatocellular carcinoma (HCC), while evidence regarding its efficacy for primary intrahepatic cholangiocarcinoma (iCCA) is lacking. The goal of this observational study is to study the efficacy of ablation in treating iCCA by comparing its prognosis with surgery. The main questions it aims to answer are:\n\n* Whether microwave ablation could achieve similar efficacy with liver resection in treating iCCA\n* What is the risk factor for ablation or surgery in treating iCCA\n* What kind of iCCA patients could receive ablation as their first-line treatment In this real-world multicenter cohort study, we will collect data of iCCA patients from hospitals who underwent microwave ablation (MWA) or liver resection (LR) for tumors within Milan criteria. Survival will be compared between patients treated by MWA or LR.",[59,27],"2024-07-24",{"date":87,"type":32},"2024-07-25",{"date":89,"type":32},"2009-01-01",{"date":91,"type":21},"2029-06-01",{"name":93,"class":39},"Chinese PLA General Hospital",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":72},"100547145","pulmonary-watershed-topographic-map-navigation-for-lung-nodule-resection-100547145","NCT06404164","Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection","Artificial Intelligence Pulmonary Watershed Terrain Navigation System for Lung Nodule Localization and Lung Function Preservation","Inclusion Criteria:\n\n1. \\\u003C1cm CTR≤0.75; \\\u003C1.5cm CTR≤0.5; \\\u003C2cm CTR≤0.25 Lung nodules\n2. The tumor center is located in the peripheral 2\u002F3 area of the lung field\n3. Preoperative analysis and planning of watershed by 3D reconstruction\n4. Clinically assessed as cT1aN0M0 stage IA1\u002FcT1bN0M0 stage IA2 (eighth edition), clinically resectable\n\nExclusion Criteria:\n\n1. No surgical video, no postoperative gross specimen and related distance measurement records\n2. The incision edge does not exceed the target nodule diameter from the nodule edge\n3. The resection range exceeds 50% of the preoperative planning\n4. Postoperative pathological staging non-pT1aN0M0 IA1 stage\u002FpT1bN0M0 IA2 stage (eighth edition)\n5. Any situation where the investigator feels the need for extended resection\n6. Patients with chronic diseases (such as COPD, pulmonary fibrosis, silicosis) that can cause loss of lung function in patients at risk of progression or potential progression",{"count":102,"type":21},3000,[104],"NA","A method of ICG counterstaining localization under target artery occlusion without cutting，It's a new method of localization of small pulmonary nodules.",[107,108,109],"Pulmonary Function Assessment","Disease Free Survival","NSCLC, Stage I",[111,112],"Watershed Analysis","wedge resection","2024-05-04",{"date":115,"type":32},"2024-05-08",{"date":117,"type":32},"2022-01-30",{"date":119,"type":21},"2027-12-30",{"name":121,"class":39},"Guangdong Provincial People's Hospital"]